Cannara Biotech announces FY25 EPS of C$0.14, up from C$0.07 the previous year

Strong Financial Performance: Cannara Biotech reported a record FY25 revenue of C$107.3M, reflecting significant year-over-year growth across key financial metrics, including adjusted EBITDA and net income.

Market Share Gains: The company increased its national market share by nearly 32% to 3.81% and its provincial market share in Quebec by over 53% to 12.72%, demonstrating strong consumer loyalty.

Future Initiatives: Cannara is focused on launching a new vape category in Quebec and plans to expand its cultivation capacity by operationalizing additional grow rooms at its Valleyfield facility over the next four years.

Tribute to Leadership: The company acknowledged the passing of Jack M. Kay, a board member since 2019, recognizing his impactful leadership and contributions to Cannara.